Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors as a Single Agent and in Combination With Ipilimumab

NCT02304458 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT02304458
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02304458 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors as a Single Agent and in Combination With Ipilimumab
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1/2
Overall status
Completed
Start date
March 30, 2015
Completion date
March 31, 2023
Enrollment
140 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic melanoma, recurrent ewing sarcoma/peripheral primitive neuroectodermal tumor, recurrent hodgkin lymphoma, recurrent malignant solid neoplasm, recurrent melanoma, recurrent neuroblastoma, recurrent non-hodgkin lymphoma, recurrent osteosarcoma, recurrent rhabdomyosarcoma, refractory ewing sarcoma/peripheral primitive neuroectodermal tumor, refractory hodgkin lymphoma, refractory malignant solid neoplasm, refractory melanoma, refractory neuroblastoma, refractory non-hodgkin lymphoma, refractory osteosarcoma, refractory rhabdomyosarcoma, stage iii cutaneous melanoma ajcc v7, stage iiia cutaneous melanoma ajcc v7, stage iiib cutaneous melanoma ajcc v7, stage iiic cutaneous melanoma ajcc v7, stage iv cutaneous melanoma ajcc v6 and v7, unresectable melanoma